ARGX-117
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delayed Graft Function
Conditions
Delayed Graft Function
Trial Timeline
Feb 17, 2024 → Jul 31, 2026
NCT ID
NCT05907096About ARGX-117
ARGX-117 is a phase 2 stage product being developed by Argenx for Delayed Graft Function. The current trial status is active. This product is registered under clinical trial identifier NCT05907096. Target conditions include Delayed Graft Function.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05907096 | Phase 2 | Active |
| NCT05405361 | Phase 2 | Active |
| NCT05225675 | Phase 2 | Completed |
Competing Products
8 competing products in Delayed Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Lemborexant + Placebo | Eisai | Approved | 85 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 32 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 51 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Desflurane + Propofol | Baxter | Approved | 82 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |